Arcus Biosciences, Inc.
RCUS
$9.16
$0.030.33%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.00M | 26.00M | 48.00M | 39.00M | 145.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.00M | 26.00M | 48.00M | 39.00M | 145.00M |
| Cost of Revenue | 122.00M | 101.00M | 123.00M | 10.00M | 109.00M |
| Gross Profit | -94.00M | -75.00M | -75.00M | 29.00M | 36.00M |
| SG&A Expenses | 28.00M | 28.00M | 30.00M | 30.00M | 32.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 150.00M | 129.00M | 153.00M | 145.00M | 141.00M |
| Operating Income | -122.00M | -103.00M | -105.00M | -106.00M | 4.00M |
| Income Before Tax | -112.00M | -93.00M | -92.00M | -93.00M | -4.00M |
| Income Tax Expenses | -- | 1.00M | -- | -- | -- |
| Earnings from Continuing Operations | -112.00M | -94.00M | -92.00M | -93.00M | -4.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -112.00M | -94.00M | -92.00M | -93.00M | -4.00M |
| EBIT | -122.00M | -103.00M | -105.00M | -106.00M | 4.00M |
| EBITDA | -119.00M | -100.00M | -103.00M | -104.00M | 7.00M |
| EPS Basic | -1.14 | -1.03 | -1.01 | -1.02 | -0.05 |
| Normalized Basic EPS | -0.71 | -0.63 | -0.63 | -0.64 | 0.12 |
| EPS Diluted | -1.14 | -1.03 | -1.01 | -1.02 | -0.05 |
| Normalized Diluted EPS | -0.71 | -0.63 | -0.63 | -0.64 | 0.12 |
| Average Basic Shares Outstanding | 98.40M | 91.70M | 91.40M | 91.10M | 86.20M |
| Average Diluted Shares Outstanding | 98.40M | 91.70M | 91.40M | 91.10M | 86.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |